Liposomal Bupivacaine After Cesarean Delivery

Withdrawn before enrolling · Phase 4

Conditions studied: Pain, Postoperative, Opioid Use

In brief

The aim of this study is to determine if local wound infiltration with liposomal bupivacaine at the time of cesarean delivery can decrease opioid use and provide adequate post-operative pain control.

Key facts

Study ID

NCT03907813

Run by

Wright State University

People needed

0

Starts

2019-05-01

Expected to finish

2020-07-31

Last updated by the study team

2020-07-31

Who can join

Age: 18 and older, up to 45. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Are between 18 and 45 years of age, inclusive.
• Are undergoing a planned, primary or repeat, cesarean delivery without permanent sterilization.
• Have a BMI ≤ 60.
• Are able to read and understand English.

You may not qualify if…

• Have pre-eclampsia with severe features.
• Has been taking medication assisted treatment for opioid addiction during this pregnancy.
• Have known sensitivity to local anesthetic.
• Have a known sensitivity to non-steroidal anti-inflammatory medications.
• Planning to have a tubal ligation after the cesarean delivery.
• Are unable to receive neuraxial analgesia and/or Duramorph, a morphine formulation that is the standard of care for intrathecal anesthesia at MVH.
• Are prisoners.

Where it is running

• Miami Valley Hospital — Dayton, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.